Effect of prolonged release fampridine on quality of life, walking speed and functional goal attainment in people with severe MS related walking impairment.

Trial Profile

Effect of prolonged release fampridine on quality of life, walking speed and functional goal attainment in people with severe MS related walking impairment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2015 New trial record
    • 13 Sep 2014 Interim results (n=56) presented at the 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top